ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Press
August 6, 2024
11 Sep 2023

Acarix beslutar om företrädesemission om cirka 54 MSEK fullt garanterad av bland annat en dansk life science fond

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAP...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Sep 2023

Acarix resolves on a rights issue of approximately SEK 54 million fully guaranteed by, among others, a Danish life science fund

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, ...
Continue reading
author-avatar acarix
Press
August 6, 2024
22 May 2023

Acarix raises approximately SEK 22 million through exercise of warrants and resolves on a directed share issue

In December 2022, Acarix AB (publ) (“Acarix” or the “Company”) carried out a rights issue of shares and warrants of series 2022:U (the ...
Continue reading
author-avatar acarix
Press
August 6, 2024
22 May 2023

Acarix tillförs cirka 22 MSEK genom utnyttjandet av teckningsoptioner och beslutar om riktad nyemission

Acarix AB (publ) (“Acarix” eller “Bolaget”) genomförde under december 2022 en företrädesemission av aktier och teckningsoptioner av ser...
Continue reading
author-avatar acarix
Press
August 6, 2024
04 Apr 2023

Acarix carries out a directed share issue amounting to approximately SEK 9.5 million

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, ...
Continue reading
author-avatar acarix
Press
August 6, 2024
04 Apr 2023

Acarix genomför en riktad nyemission om cirka 9,5 MSEK

DETTA PRESSMEDDELANDE ÄR EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AU...
Continue reading
author-avatar acarix
Press
August 6, 2024
23 Jan 2023

Acarix announces last day of trading with BTU and first day of trading in warrants

THIS ANNOUNCEMENT IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, C...
Continue reading
author-avatar acarix
Press
August 6, 2024
23 Jan 2023

Acarix meddelar sista dag för handel med BTU och första dag för handel med teckningsoptioner

DETTA PRESSMEDDELANDE ÄR EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AU...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Jan 2023

Acarix carries out a directed issue of shares to guarantors in connection with the completed rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Jan 2023

Acarix genomför riktad nyemission av aktier till garanter i samband med den genomförda företrädesemissionen

DETTA PRESSMEDDELANDE ÄR EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AU...
Continue reading
author-avatar acarix
Press
August 6, 2024
03 Jan 2023

Acarix announces final outcome of rights issue

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
Continue reading
author-avatar acarix
Press
August 6, 2024
03 Jan 2023

Acarix offentliggör slutligt utfall i företrädesemission

DETTA PRESSMEDDELANDE ÄR EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AU...
Continue reading
  • 1
  • 2
  • 3
  • 4
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
info@acarix.com

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • News
  • Press
  • Events
  • Cookie policy
  • Full Disclaimer
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Full Disclaimer
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2023. All rights reserved V5

  • Products
    • Background
      • What is Coronary Artery Disease
      • Diagnosing CAD
    • About the product
      • The Cadscor System
      • How Does it Work
  • Resources
    • Testimonial
      • HCP Stories
      • Patients Stories
    • References
      • Clinical Studies
      • Downloads (US)
      • Downloads (EU)
    • Support
      • Training
      • Faq
      • Reimbursement
    • Physician Locator
      • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
      • About Acarix
      • Leadership
      • Join The Team
    • Get in touch
      • Contact Us
      • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.